BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31472746)

  • 1. Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.
    Elschot M; Selnæs KM; Langørgen S; Johansen H; Bertilsson H; Tandstad T; Bathen TF
    PET Clin; 2019 Oct; 14(4):487-498. PubMed ID: 31472746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with
    Sobol I; Zaid HB; Haloi R; Mynderse LA; Froemming AT; Lowe VJ; Davis BJ; Kwon ED; Karnes RJ
    J Urol; 2017 Jan; 197(1):129-134. PubMed ID: 27449262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
    Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
    Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
    D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.
    Souvatzoglou M; Krause BJ; Pürschel A; Thamm R; Schuster T; Buck AK; Zimmermann F; Molls M; Schwaiger M; Geinitz H
    Radiother Oncol; 2011 May; 99(2):193-200. PubMed ID: 21620494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
    Meijer D; Luiting HB; van Leeuwen PJ; Remmers S; Jansen BHE; Bodar YJL; Witteveen T; Schaake EE; van der Poel HG; Wondergem M; Busstra MB; Nieuwenhuijzen JA; Meijnen P; Brabander T; van Moorselaar RJA; Hendrikse NH; Oprea-Lager DE; Roobol MJ; Vis AN
    J Urol; 2021 Apr; 205(4):1100-1109. PubMed ID: 33207138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radical salvage prostatectomy : Treatment of local recurrence of prostate cancer after radiotherapy].
    Heidenreich A; Semrau R; Thüer D; Pfister D
    Urologe A; 2008 Nov; 47(11):1441-6. PubMed ID: 18806991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
    J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
    Chang JH; Park W; Park JS; Pyo H; Huh SJ; Choi HY; Lee HM; Jeon SS; Seo SI
    Int J Urol; 2015 Jan; 22(1):82-7. PubMed ID: 25208624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
    Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
    Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
    Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
    Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.